# US 2026/0098032 A1 · METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098032 A1
- Document ID: US20260098032A1
- Status: Published application
- Kind: A1
- Application number: 19/209,328
- Filed: 2025-05-15
- Published: 2026-04-09
- Earliest claimed: 2019-09-23
- Assignees: Pmv Pharmaceuticals, Inc.
- Applicants: PMV Pharmaceuticals, Inc.
- Inventors: Binh VU; Romyr DOMINIQUE; Hongju LI; Bruce FAHR; Andrew GOOD
- Web page: https://patentgrep.com/patent/US20260098032A1

## CPC

- C07D 405/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D 209/10: with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 409/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D 471/04: Ortho-condensed systems
- C07D 471/08: Bridged systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 498/06: Peri-condensed systems
- C07D 498/08: Bridged systems
- C07F 7/0812: {comprising a heterocyclic ring}
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

## Claims

### Claim at position 1

1-236. (canceled)

### Claim 237

A compound comprising:
a heterocyclyl group comprising a halogen substituent,
wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant p53 protein.

### Claim 238 (depends on 237)

The compound of claim 237, wherein the compound further comprises an indole group attached to the heterocyclyl group.

### Claim 239 (depends on 238)

The compound of claim 238, wherein the indole group has a 1,1,1-trifluoroethyl substituent at a 1-position of the indole group.

### Claim 240 (depends on 238)

The compound of claim 238, wherein the indole group has a propargyl substituent at a 2-position of the indole group.

### Claim 241 (depends on 240)

The compound of claim 240, wherein the propargyl substituent is attached to the indole group via an sp carbon atom of the propargyl substituent.

### Claim 242 (depends on 240)

The compound of claim 240, wherein the propargyl substituent is attached to a nitrogen atom of an aniline group via a methylene group of the propargyl substituent.

### Claim 243 (depends on 238)

The compound of claim 238, wherein the indole group comprises an amino substituent at a 4-position of the indole group.

### Claim 244 (depends on 243)

The compound of claim 243, wherein the amino substituent is attached to the heterocyclyl group.

### Claim 245 (depends on 238)

The compound of claim 238, wherein the heterocyclyl group is a piperidine group.

### Claim 246 (depends on 245)

The compound of claim 245, wherein the heterocyclyl group is a methylpiperidine group that is unsubstituted or substituted.

### Claim 247 (depends on 246)

The compound of claim 246, wherein the heterocyclyl group is 3-fluoro-1-methylpiperidin-4-yl.

### Claim 248 (depends on 237)

The compound of claim 237, wherein the compound has oral bioavailability that is at least about 50% greater than that of an analogous compound that lacks the halogen substituent on the heterocyclic group.

### Claim 249

A method of preparing a pharmaceutical composition, the method comprising contacting a compound with a pharmaceutically-acceptable carrier selected from water, ethanol, isopropanol, saline, physiological saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate buffer saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino) propanesulfonic acid buffer (MOPS), piperazine-N,N′-bis(2-ethanesulfonic acid) buffer (PIPES), and saline sodium citrate buffer (SSC), wherein the compound is of the formula:
wherein:
each is independently a single bond or a double bond;
X1 is CR5, CR5R6, N, NR5, O, S, C═O, C═S, or a carbon atom connected to Q1;
X2 is CR7, CR7R8, N, NR7, O, S, C═O, C═S, or a carbon atom connected to Q1;
X3 is CR9, CR9R10, N, NR9, O, S, C═O, C═S, or a carbon atom connected to Q1;
X4 is CR11, CR11R12, N, NR11, O, S, C═O, C═S, or a carbon atom connected to Q1;
X5 is CR13, N, or NR13;
wherein at least one of X1, X2, X3, and X4 is a carbon atom connected to Q1;
Q1 is C═O, C═S, C═CR14R15, C═NR14, alkylene, alkenylene, or alkynylene, each of which is independently substituted or unsubstituted, or a bond;
m is 1, 2, 3, or 4;
Y is N, O, or absent;
R1 is —C(O)R16, —C(O)OR16, —C(O)NR16R17, —OR16, —SR16, —NR16R17, —NR16C(O)R16, —OC(O)R16, C═O, C═S, —CN, —SiR16R17R18, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen;
each R3 and R4 is independently, —C(O)R19, —C(O)OR19, —C(O)NR19R20, —SOR19, —SO2R19, alkyl, alkylene, alkenyl, alkenylene, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen, or R3 and R4 together with the Y atom to which R3 and R4 are bound form a ring, wherein the ring is substituted or unsubstituted, or R3 is absent;
each R2, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, and R18 is independently —C(O)R21, —C(O)OR21, —C(O)NR21R22, —OR21, —SR21, —NR21R22, —NR21C(O)R22, —OC(O)R21, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
each R19 and R20 is C(O)R23, —C(O)OR23, —C(O)NR23R24, —OR23, —SR23, —NR23R24, —NR23C(O)R24, —OC(O)R23, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen or halogen;
each R21 and R22 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen; and
each R23 and R24 is independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl, each of which is independently substituted or unsubstituted, or hydrogen,
or a pharmaceutically-acceptable salt thereof, wherein the compound is not a compound of Table 1.

### Claim 250 (depends on 249)

The method of any one of claim 249, wherein Q1 is a bond.

### Claim 251 (depends on 249)

The method of any one of claim 249, wherein m is 1.

### Claim 252 (depends on 249)

The method of any one of claim 249, wherein m is 2.

### Claim 253 (depends on 249)

The method of any one of claim 249, wherein Y is N or O.

### Claim 254 (depends on 249)

The method of any one of claim 249, wherein R4 is heterocyclyl substituted at least with fluoro-.

### Claim 255 (depends on 249)

The method of any one of claim 249, wherein R4 is substituted piperidinyl.

### Claim 256 (depends on 249)

The method of any one of claim 249, wherein R2 is substituted alkyl.
